Development of anti-tauopathy drugs using C. elegans.
| Project/Area Number |
22650074
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Nerve anatomy/Neuropathology
|
|---|
| Research Institution | Doshisha University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,330,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | タウ / タウオパチー / アルツハイマー病 / 神経細胞死 / 線虫 / 認知症 / クルクミン / 創薬 / チューブリン |
|---|
| Research Abstract |
Tauopathy is a category of neurodegenerative disease, which develops tau accumulation in the affected neurons. Because the mechanisms of neurodegeneration of tauopathy remain obscure, screening of anti-tauopathy compounds must be processed using in vivo model, which can assess the neuronal dysfunction affected by abnormal tau. Purposes of this study are 1, to develop the in vivo drug screening system that combines C. elegans model of tauopathy and fluorescence based motion tracking(FMT) system, and 2, to perform direct screening of the anti-tauopathy compounds possibly ameliorate tau-induced neuronal dysfunction using the C. elegans models.
|
Report
(3 results)
Research Products
(6 results)
